

Reliance Life Sciences' candidate is in Phase I clinical trials. "The vaccine has a unique construct, which is expected to be effective against a range of Covid-19 virus variants, going by data from extensive in-vitro and animal studies. Human clinical trials would have to reaffirm the safety and efficacy," says K.V. Subramaniam, President, Reliance Life Sciences.



**K.V. Subramaniam**

President of Reliance Life Sciences